

DAFTAR PUSTAKA

- Agarwal D, Chakravarty J, Lavina C, Madhukar R, Nisha RA & Shyam S. (2010). High Incidence of Zidovudine Induced Anaemia in HIV Infected Patients in Eastern India. *Indian J Med Res*, 132 : 386-389.
- Ayele, G. *et al.* (2018) 'Prevalence and associated factors of treatment failure among HIV/AIDS patients on HAART attending University of Gondar Referral Hospital Northwest Ethiopia', *BMC Immunology*. BMC Immunology, 19(1), pp. 1–13. doi: 10.1186/s12865-018-0278-4.
- Babo, Y. D., Alemie, G. A. and Fentaye, F. W. (2017) 'Predictors of first-line antiretroviral therapy failure amongst HIV-infected adult clients at Woldia Hospital, Northeast Ethiopia', *PLoS ONE*, 12(11), pp. 1–19. doi: 10.1371/journal.pone.0187694.
- Balestre, E. *et al.* (2012) 'Effect of age on immunological response in the first year of antiretroviral therapy in HIV-1-infected adults in West Africa', *Aids*, 26(8), pp. 951–957. doi: 10.1097/QAD.0b013e3283528ad4.
- Bayu, B. *et al.* (2017) 'Determinants of virological failure among patients on highly active antiretroviral therapy in University of Gondar Referral Hospital, Northwest Ethiopia: A case-control study', *HIV/AIDS - Research and Palliative Care*, 9, pp. 153–159. doi: 10.2147/HIV.S139516.
- Belasio, E. F. *et al.* (2010) 'HIV Virology and Pathogenetic Mechanism of Infection: a Brief Overview', *Ann Ist Super Sanità*, 46(1), pp. 5–14. doi: 10.4415/Ann.
- van den Berg, J. B. *et al.* (2005) 'Increased risk of early virological failure in non-European HIV-1-infected patients in a Dutch cohort on highly active antiretroviral therapy', *HIV Medicine*, 6(5), pp. 299–306. doi: 10.1111/j.1468-1293.2005.00304.x.
- Centers for Disease Control and Prevention (2013) 'Managing Drug Related Interactions in the Face of HIV- Related Tuberculosis', p. 32. Available at: http://www.cdc.gov/tb/publications/guidelines/tb_hiv_drugs/pdf/tbhiv.pdf.
- Endebu, T. *et al.* (2018) 'Incidence of Virological Failure and Associated Factors among Adult HIV-Positive Patients on First Line Antiretroviral Therapy Regimen , Central Ethiopia', 4(2), pp. 44–51. doi: 10.11648/j.ijhpebs.20180402.13.
- Engelman, Alan; Cherepanov, P. (2013) 'Nihms443312', *Nature reviews. Microbiology*, 10(4), pp. 279–290. doi: 10.1038/nrmicro2747.The.
- Fatti, G. *et al.* (2014) 'Antiretroviral treatment outcomes amongst older adults in a large multicentre cohort in South Africa', *PLoS ONE*, 9(6), pp. 1–9. doi: 10.1371/journal.pone.0100273.
- Gardner, E. M. *et al.* (2009) 'Antiretroviral medication adherence and the development of class-specific antiretroviral resistance', *Aids*, 23(9), pp. 1035–1046. doi: 10.1097/QAD.0b013e32832ba8ec.
- Geretti, A. M. *et al.* (2008) 'Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy', *Antiviral Therapy*, 13(7), pp. 927–936.
- Hailu, G. G. *et al.* (2018) 'Virological and immunological failure of HAART and associated risk factors among adults and adolescents in the Tigray region of Northern Ethiopia', *PLoS ONE*, 13(5), pp. 1–17. doi:

- 10.1371/journal.pone.0196259.
- Indonesia, K. K. (no date) ‘Laporan_Perkembangan_HIV_AIDS___PIMS_TRIWULAN_IV_TAHU N_2019.pdf’. Jakarta: Kementerian Kesehatan Indonesia.
- Kan, W. et al. (2017a) ‘Predictors of HIV virological failure and drug resistance in Chinese patients after 48 months of antiretroviral treatment, 2008-2012: A prospective cohort study’, *BMJ Open*, 7(9), pp. 1–15. doi: 10.1136/bmjopen-2017-016012.
- Kan, W. et al. (2017b) ‘Predictors of HIV virological failure and drug resistance in Chinese patients after 48 months of antiretroviral treatment, 2008-2012: A prospective cohort study’, *BMJ Open*, 7(9). doi: 10.1136/bmjopen-2017-016012.
- Kazooba, P. et al. (2018) ‘Virological failure on first-line antiretroviral therapy; associated factors and a pragmatic approach for switching to second line therapy—Evidence from a prospective cohort study in rural south-western Uganda, 2004-2011’, *Pan African Medical Journal*, 29. doi: 10.11604/pamj.2018.29.191.11940.
- Kim, J. et al. (2018) ‘Adherence to antiretroviral therapy and factors affecting low medication adherence among incident HIV-infected individuals during 2009-2016: A nationwide study’, *Scientific Reports*. Springer US, 8(1), pp. 1–8. doi: 10.1038/s41598-018-21081-x.
- Kiweewa, F. et al. (2019) ‘HIV virologic failure and its predictors among HIV-infected adults on antiretroviral therapy in the African Cohort Study’, *PLoS ONE*, 14(2), pp. 1–16. doi: 10.1371/journal.pone.0211344.
- Lagat, K. (Lahti U. of A. S. D. P. in N. (2018) ‘FACTORS LEADING TO FASTER PROGRESSION OF HIV TO AIDS’.
- Leng, X. et al. (2014) ‘HIV virological failure and drug resistance among injecting drug users receiving first-line ART in China’, *BMJ Open*, 4(10), pp. 1–7. doi: 10.1136/bmjopen-2014-005886.
- Luber, A. D. (2005) ‘Journal of the International AIDS Society Genetic Barriers to Resistance and Impact on Clinical’, 10, pp. 1–10.
- Maartens, G., Celum, C. and Lewin, S. R. (2014) ‘HIV infection: Epidemiology, pathogenesis, treatment, and prevention’, *The Lancet*. Elsevier Ltd, 384(9939), pp. 258–271. doi: 10.1016/S0140-6736(14)60164-1.
- Mali, S. N. and Sapkal, P. M. (2015) ‘HIV Drug Resistance: An Overview’, *Human Journals Review Article October*, 1(11), pp. 72–82.
- Mboi, N. and Smith, K. H. (2006) ‘Indonesia: Current Status of HIV/AIDS in Indonesia and Prospects for its Spread’, *Fighting a Rising Tide: The Response to AIDS in East Asia*, pp. 96–118.
- Menkes (2019) ‘No 主観的健康感を中心とした在宅高齢者における 健康 関連指標に関する共分散構造分析Title’, *Keputusan Menteri Kesehatan Republik Indonesia Nomor HK 01.07/Menkes/90/2019. Pedoman Nasional Pelayanan Kedokteran Tatalaksana HIV*, pp. 1–220.
- Miller, V. et al. (2002) ‘Association of Virus Load, CD4 Cell Count, and Treatment with Clinical Progression in Human Immunodeficiency Virus-Infected Patients with Very Low CD4 Cell Counts’, *The Journal of Infectious Diseases*, 186(2), pp. 189–197. doi: 10.1086/341466.

- Ministry of Health Indonesia [Kemenkes] (2019) ‘Laporan Perkembangan HIV AIDS and STIs Triwulan IV Tahun 2018 [Quarterly Report of HIV AIDS and STIs 2018]’, p. 164. Available at: http://siha.depkes.go.id/portal/files_upload/Laporan_Triwulan_IV_2018.pdf.
- Naif, H. M. (2013) ‘Pathogenesis of HIV infection’, *Infectious Disease Reports*, 5(SUPPL.1), pp. 26–30. doi: 10.4081/idr.2013.s1.e6.
- Nasronudin (no date) ‘Buku Ajar IPD PAPDI Edisi VI.pdf’. Jakarta: Interna Publishing.
- Ofoutokun, I. (2005) ‘Sex differences in the pharmacologic effects of antiretroviral drugs: potential roles of drug transporters and phase 1 and 2 metabolizing enzymes.’, *Topics in HIV medicine : a publication of the International AIDS Society, USA*, 13(2), pp. 79–83.
- P., P. et al. (2014) ‘The vulnerability of men to virologic failure during antiretroviral therapy in a public routine clinic in Burkina Faso.’, *Journal of the International AIDS Society*, 17, p. 18646. doi: 10.7448/IAS.17.1.18646.
- Paredes, R. et al. (2000) ‘Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: Results from the EuroSIDA Study’, *Archives of Internal Medicine*, 160(8), pp. 1123–1132. doi: 10.1001/archinte.160.8.1123.
- Perhimpunan Peneliti Hati Indonesia (2014) ‘Konsensus Nasional Penatalaksanaan-Hepatitis C di Indonesia’, pp. 1–34.
- Permenkes (2017) ‘Update Tatalaksana TB Indonesia’, *Dinas Kesehatan*, p. 163.
- PPHI (2017) ‘Konsensus Nasional Penatalaksanaan Hepatitis B’. Jakarta: PPHI Indonesia. Available at: perkeni.freeservers.com/kons_dm.html.
- Ramadhani, H. O. et al. (2007) ‘Predictors of Incomplete Adherence, Virologic Failure, and Antiviral Drug Resistance among HIV-Infected Adults Receiving Antiretroviral Therapy in Tanzania’, *Clinical Infectious Diseases*, 45(11), pp. 1492–1498. doi: 10.1086/522991.
- Rastogi, S. et al. (2011) ‘Clinical Stages of HIV’, I(January), pp. 29–31.
- Rupérez, M. et al. (2015) ‘Determinants of virological failure and antiretroviral drug resistance in Mozambique’, *Journal of Antimicrobial Chemotherapy*, 70(9), pp. 2639–2647. doi: 10.1093/jac/dkv143.
- Saag, M. S. et al. (2004) ‘Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naïve patients: A randomized trial’, *Journal of the American Medical Association*, 292(2), pp. 180–190. doi: 10.1001/jama.292.2.180.
- Sari, P. T. and Rohman, A. (2015) ‘Dengan Etika Pengguna Sebagai Variabel Moderasi’, 4, pp. 1–11.
- Shaw, G. M. and Hunter, E. (2017) ‘Factors That Influence HIV Transmission’, *Cold Spring Harbor Perspectives in Medicine*, 2(11), pp. 1–23. doi: 10.1101/cshperspect.a006965.
- Shekelle, P. et al. (2007) ‘Antiretroviral (ARV) drug resistance in the developing world.’, *Evidence report/technology assessment*, (156), pp. 1–74.
- Trickey, A. et al. (2017) ‘Survival of HIV-positive patients starting

- antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies’, *The Lancet HIV*, 4(8), pp. e349–e356. doi: 10.1016/S2352-3018(17)30066-8.
- UN Joint Programme on HIV/AIDS (UNAIDS) (2014) ‘to help end the AIDS epidemic’, *United Nations*.
- Vijayan, K. V. et al. (2017) ‘Pathophysiology of CD4+ T-Cell depletion in HIV-1 and HIV-2 infections’, *Frontiers in Immunology*, 8(MAY), pp. 1–8. doi: 10.3389/fimmu.2017.00580.
- Volberding, P. A. and Deeks, S. G. (2010) ‘Antiretroviral therapy and management of HIV infection’, *The Lancet*. Elsevier Ltd, 376(9734), pp. 49–62. doi: 10.1016/S0140-6736(10)60676-9.
- von Wyl, V. et al. (2013) ‘Adherence as a Predictor of the Development of Class-Specific Resistance Mutations: The Swiss HIV Cohort Study’, *PLoS ONE*, 8(10), pp. 1–11. doi: 10.1371/journal.pone.0077691.
- Zaccarelli, M. et al. (2002) ‘Factors Related to Virologic Failure among HIV-Positive’, 16(2).
- Zdanowicz, M. M. (2006) ‘The pharmacology of HIV drug resistance’, *American Journal of Pharmaceutical Education*, 70(5). doi: 10.5688/aj7005100.
- Zhou, J. et al. (2010) ‘Trends in CD4 counts in HIV-infected patients with HIV viral load monitoring while on combination antiretroviral treatment: Results from The TREAT Asia HIV Observational Database’, *BMC Infectious Diseases*, 10. doi: 10.1186/1471-2334-10-361.